Skip to main content
Home
FDA
  • START A TRIAL
  • LOG IN
  • Thompson FDA
  • Manage Account
  •  
  •  
  • 1.800.677.3789

Main navigation

  • LIBRARY
    • FDA Enforcement Manual
    • Guide to Good Clinical Practice
    • FDA Advertising and Promotion Manual
    • Guide to Medical Device Regulation
    • Guide to U.S. Food Labeling Law
  • MY RESEARCH
  • NEWS
    • All News
    • FDA Intelligence
  • DATABASES
    • FDA Enforcement Database
    • Clinlaw State Database
  • RESOURCES
    • FDA Forms
    • Special Reports
    • Judicial Opinions
    • Webinars
    • Interactive Tools
  • AGENCY GUIDANCE
    • Enforcement Guidance
    • Clinical Trials Guidance
    • Advertising and Promotion Guidance
    • Medical Device Guidance
    • Food Labeling Guidance
  • ASK THE EXPERT

Login to the Thompson
FDA Compliance Expert

Enter your FDA username.
Enter the password that accompanies your username.
Forgot password?

Not Yet A Subscriber?
Click here to register for a free trial

Questions? Give us a call! 1-800-677-3789

Advertising & Promotion

  • Jan 11, 2021
    N.Y. Assembly Bill Aims To Keep Individual Prescribing Data Confidential
  • Jan 6, 2021
    FDA Debars Three Former Insys Executives
  • Dec 29, 2020
    Senate Report Calls for Adding Payments to Tax-exempt Groups to Open Payments Database
  • Dec 21, 2020
    Drug Company and Specialty Pharmacy Settle False Claims Act Case Over Payments to Foundations
  • Dec 16, 2020
    OPDP Researchers Move Ahead with Endorsement Studies, Report on Completed Research
  • Dec 4, 2020
    OPDP Issues Second Untitled Letter of 2020
  • Dec 2, 2020
    Companies Settle FCA Case Over Improper Promotion of Drug-Device Combo Product for Pediatric Use
  • Nov 24, 2020
    OPDP Adds Five-day Screening Period to Core Launch Review
  • Nov 17, 2020
    HHS OIG Issues Special Fraud Alert on Speaker Programs
  • Nov 8, 2020
    Medtronic Agrees To Pay $9.2 Million To Settle FCA Case
  • More

Good Clinical Practice

  • Nov 10, 2020
    FDA Issues Final Guidance on Trial Diversity
  • Nov 2, 2020
    SACHRP Recommends that HHS Narrowly Interpret Revised Common Rule Exclusion of Public Health Surveillance
  • Oct 23, 2020
    OHRP Allows Single IRB Review Exception for Some COVID-19 Research
  • Oct 20, 2020
    Investigator Sentenced to More Than 28 Years for Falsifying Clinical Trial Safety and Efficacy Data
  • Oct 13, 2020
    NHLBI Trial Changes Protocol and Informed Consent After Public Citizen Complaint to OHRP
  • Oct 8, 2020
    NIH Launches COVID-19 Outreach Program Targeting Minority Communities
  • Oct 1, 2020
    Study Finds Elderly Excluded from COVID-19 Trials
  • Sep 23, 2020
    Revised Guidance Details Investigator Review of Safety Reports in Trials Conducted During Pandemic
  • Sep 16, 2020
    FDA Issues Guidance on Measuring and Analyzing Common COVID-19 Symptoms in Clinical Trials
  • Sep 9, 2020
    ACRO Publishes Manual and Toolkit for Conducting Decentralized Clinical Trials
  • More

U.S. Food Labeling

  • Jan 7,2021
    ANPR Issued on USDA’s Oversight of Genetically Engineered Animals
  • Jan 7,2021
    Petition Seeks Dietary Fiber Consideration for Gum Acacia
  • Jan 7,2021
    FDA Sets New Food Labeling Uniform Compliance Date
  • Jan 7,2021
    Supplement Firm Owner Pleads Guilty to Drug Distribution
  • Jan 7,2021
    FDA Warns Retailer About Undeclared Allergens
  • Dec 23,2020
    FDA Finalizes Labeling Guidance on Alternate Name for Potassium Chloride
  • Dec 10,2020
    Court Refuses To Enjoin Oklahoma Plant-Based Meat Labeling Law; Plaintiffs Appeal
  • Nov 24,2020
    House Passes Bill To Add Sesame to Regulated List of Allergens
  • Nov 12,2020
    FDA Posts Draft Guidance on Voluntary Disclosure of Sesame as Allergen
  • Oct 29,2020
    FDA Wants Feedback on Labeling ‘Nontraditional’ Sugars
  • More

FDA Regulation & Enforcement

  • Dec 29, 2020
    Senate Report Calls for Adding Payments to Tax-exempt Groups to Open Payments Database
  • Dec 24, 2020
    Device Company CEO Charged with Securities Fraud for Falsely Claiming Development of COVID-19 Test
  • Dec 23, 2020
    Court: Product Liability Claims Involving Contaminated Valsartan Not Preempted under FD&C Act, DSCSA
  • Dec 23, 2020
    FDA Finalizes Labeling Guidance on Alternate Name for Potassium Chloride
  • Dec 21, 2020
    Drug Company and Specialty Pharmacy Settle False Claims Act Case Over Payments to Foundations
  • Dec 16, 2020
    N.C. Company, Owner Plead Guilty to Marketing Unapproved Steroid-like Drugs as Sports Supplements
  • Dec 16, 2020
    Catheter Maker Issues Urgent Recall of Device Following Reports of 14 Deaths, Hundreds of Injuries
  • Dec 16, 2020
    OPDP Researchers Move Ahead with Endorsement Studies, Report on Completed Research
  • Dec 10, 2020
    District Court: State Law Tort Claims Related to PMA Cardiac Device Are Not Preempted by Federal Law
  • Dec 10, 2020
    Court Refuses To Enjoin Oklahoma Plant-Based Meat Labeling Law; Plaintiffs Appeal
  • More

Medical Devices

  • Jan 14, 2021
    HHS Permanently Exempts Seven COVID-19-Related Medical Devices from FDA’s 510(k) Requirements
  • Jan 7, 2021
    Congress Expands FDA’s Administrative Destruction Authority To Include Imported Medical Devices
  • Jan 7, 2021
    FDA Finalizes Guidance for Program Offering Expedited Review for Devices with Safer Technologies
  • Dec 30, 2020
    FDA Finalizes Labeling Guidance, Updates Safety Communication on Laparoscopic Power Morcellators
  • Dec 24, 2020
    Device Company CEO Charged with Securities Fraud for Falsely Claiming Development of COVID-19 Test
  • Dec 16, 2020
    Catheter Maker Issues Urgent Recall of Device Following Reports of 14 Deaths, Hundreds of Injuries
  • Dec 10, 2020
    District Court: State Law Tort Claims Related to PMA Cardiac Device Are Not Preempted by Federal Law
  • Dec 2, 2020
    CISA: Cybersecurity Vulnerability in BD Alaris Infusion Pumps Could Affect Wireless Capability
  • Dec 2, 2020
    GAO Finds Persistent COVID-19 Supply Shortages, Inconsistent Testing Guidance from Federal Agencies
  • Nov 25, 2020
    Final Guidance on Microneedling Devices Reflects Class II Classification for Aesthetic Use Products
  • More

THOMPSON FDA

  • Thompson FDA
  • About Us
  • Manage Account
  • Our Parent Company

COMPLIANCE EXPERT

  • News
  • My Research
  • Our Experts
  •  

RESOURCES

  • FDA Forms
  • Special Reports
  • Webinars
  •  

HELP

  • Customer Support
  •  
  •  
  •  
  •  

CONTACT

  • Headquarters
  • 1.800.677.3789
  • service@thompson.com
  •   

Copyright © Thompson FDA, a division of CBIS. All rights reserved.

  • Terms
  • Privacy